// App-Quantinova.ai

3539 : Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.

Researchers

Presenter

  • Neil Howard Segal

Principal Investigators

  • Nancy E. Kemeny

  • Andrea Cercek

  • Diane Lauren Reidy

  • Pamela Joan Raasch

  • Peter Warren

  • Anastasia E. Hrabovsky

  • Naomi Campbell

  • Jinru Shia

  • Karyn A. Goodman

  • Joseph Patrick Erinjeri

  • Stephen Barnett Solomon

  • Yoshiya Yamada

  • Leonard Saltz

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II

Study Id's

  • NCT02437071

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved